Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01828112
Title	LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	lung non-small cell carcinoma
Therapies	Docetaxel Pemetrexed Disodium Ceritinib
Age Groups:	adult
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL